PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Gross profit growth of 100.00% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
-1.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.47%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.63%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.63%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.22%
Share count expansion well above AVXL's 2.51%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
3.22%
Diluted share count expanding well above AVXL's 2.51%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative OCF growth while AVXL is at 55.56%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-50.21%
Negative FCF growth while AVXL is at 55.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.36%
10Y OCF/share CAGR above 1.5x AVXL's 37.35%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
62.52%
5Y OCF/share CAGR is similar to AVXL's 59.46%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
-48.56%
Negative 3Y OCF/share CAGR while AVXL stands at 42.49%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
94.18%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
69.28%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
-24.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-50.75%
Negative equity/share CAGR over 10 years while AVXL stands at 103.39%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-32.62%
Negative 5Y equity/share growth while AVXL is at 332.07%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-67.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.75%
R&D dropping or stable vs. AVXL's 22.01%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-21.32%
We cut SG&A while AVXL invests at 2.47%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.